BACKGROUND: The Red Queen hypothesis is an evolutionary theory that describes the reciprocal coevolution of competing species. We sought to study whether introduction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serotype dynamics among children with invasive pneumococcal disease (IPD) as predicted by the Red Queen hypothesis. METHODS: This study examined pneumococcal isolates (n = 641) obtained from children <18 years of age hospitalized with IPD from 1997 to 2014 in Utah. A review of the literature also identified several additional studies conducted in the United States and Europe that were used to test the external generalizability of our Utah findings. Simpson's index was used to quantify pneumococcal serotype diversity. RESULTS: In Utah, the introduction of PCV7 and PCV13 was associated with rapid increases in serotype diversity (P < .001). Serotypes rarely present before vaccine introduction emerged as common causes of IPD. Diversity then decreased (P < .001) as competition selected for the fittest serotypes and new evolutionary equilibriums were established. This pattern was also observed more broadly in the United States, the United Kingdom, Norway, and Spain. CONCLUSIONS: This vaccine-driven example of human/bacterial coevolution appears to confirm the Red Queen hypothesis, which reveals a limitation of serotype-specific vaccines and offers insights that may facilitate alternative strategies for the elimination of IPD.
BACKGROUND: The Red Queen hypothesis is an evolutionary theory that describes the reciprocal coevolution of competing species. We sought to study whether introduction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serotype dynamics among children with invasive pneumococcal disease (IPD) as predicted by the Red Queen hypothesis. METHODS: This study examined pneumococcal isolates (n = 641) obtained from children <18 years of age hospitalized with IPD from 1997 to 2014 in Utah. A review of the literature also identified several additional studies conducted in the United States and Europe that were used to test the external generalizability of our Utah findings. Simpson's index was used to quantify pneumococcal serotype diversity. RESULTS: In Utah, the introduction of PCV7 and PCV13 was associated with rapid increases in serotype diversity (P < .001). Serotypes rarely present before vaccine introduction emerged as common causes of IPD. Diversity then decreased (P < .001) as competition selected for the fittest serotypes and new evolutionary equilibriums were established. This pattern was also observed more broadly in the United States, the United Kingdom, Norway, and Spain. CONCLUSIONS: This vaccine-driven example of human/bacterial coevolution appears to confirm the Red Queen hypothesis, which reveals a limitation of serotype-specific vaccines and offers insights that may facilitate alternative strategies for the elimination of IPD.
Authors: Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Anne J Blaschke; Hsin Yi Cindy Weng; Kent E Korgenski; Judy Daly; Carrie L Byington Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Colin A Russell; Terry C Jones; Ian G Barr; Nancy J Cox; Rebecca J Garten; Vicky Gregory; Ian D Gust; Alan W Hampson; Alan J Hay; Aeron C Hurt; Jan C de Jong; Anne Kelso; Alexander I Klimov; Tsutomu Kageyama; Naomi Komadina; Alan S Lapedes; Yi P Lin; Ana Mosterin; Masatsugu Obuchi; Takato Odagiri; Albert D M E Osterhaus; Guus F Rimmelzwaan; Michael W Shaw; Eugene Skepner; Klaus Stohr; Masato Tashiro; Ron A M Fouchier; Derek J Smith Journal: Vaccine Date: 2008-09-12 Impact factor: 3.641
Authors: Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: E Pérez-Trallero; J M Marimon; M Ercibengoa; D Vicente; E G Pérez-Yarza Journal: Eur J Clin Microbiol Infect Dis Date: 2009-01-20 Impact factor: 3.267
Authors: Stefan Flasche; Albert Jan Van Hoek; Elizabeth Sheasby; Pauline Waight; Nick Andrews; Carmen Sheppard; Robert George; Elizabeth Miller Journal: PLoS Med Date: 2011-04-05 Impact factor: 11.069
Authors: Daniel M Weinberger; Krzysztof Trzciński; Ying-Jie Lu; Debby Bogaert; Aaron Brandes; James Galagan; Porter W Anderson; Richard Malley; Marc Lipsitch Journal: PLoS Pathog Date: 2009-06-12 Impact factor: 6.823
Authors: Eric Lewitus; Eric Sanders-Buell; Meera Bose; Anne Marie O'Sullivan; Kultida Poltavee; Yifan Li; Hongjun Bai; Thembi Mdluli; Gina Donofrio; Bonnie Slike; Hong Zhao; Kim Wong; Lennie Chen; Shana Miller; Jenica Lee; Bahar Ahani; Steven Lepore; Sevan Muhammad; Rebecca Grande; Ursula Tran; Vincent Dussupt; Letzibeth Mendez-Rivera; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Robert J O'Connell; Holly Janes; Peter B Gilbert; Robert Gramzinski; Sandhya Vasan; Merlin L Robb; Nelson L Michael; Shelly J Krebs; Joshua T Herbeck; Paul T Edlefsen; James I Mullins; Jerome H Kim; Sodsai Tovanabutra; Morgane Rolland Journal: Virus Evol Date: 2021-07-09
Authors: Ben Vezina; John I Alawneh; Hulayyil Al-Harbi; Hena R Ramay; Martin Soust; Robert J Moore; Timothy W J Olchowy Journal: Sci Rep Date: 2021-02-04 Impact factor: 4.379
Authors: Marloes Vissers; Alienke J Wijmenga-Monsuur; Mirjam J Knol; Paul Badoux; Marlies A van Houten; Arie van der Ende; Elisabeth A M Sanders; Nynke Y Rots Journal: PLoS One Date: 2018-03-30 Impact factor: 3.240
Authors: T Gupalova; G Leontieva; T Kramskaya; K Grabovskaya; E Bormotova; D Korjevski; A Suvorov Journal: PLoS One Date: 2018-05-04 Impact factor: 3.240